When insulin use is added to the above five risk factors, the risk of developing HCC in non-cirrhotic NAFLD increases to 69.44/10,000 persons (95% CI 26.55–112.34/10,000 persons). Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.